US FDA declines to approve Aldeyra's drug for eye disorder
17/03/2026 12:33
March 17 (Reuters) - The U.S. Food and Drug Administration on Tuesday declined to approve Aldeyra Therapeutics' ALDX.O drug for a type of eye disease, the company said. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sherry Jacob-Phillips) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Alcon AG
See all newsBrief: Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2
Brief: Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2
Swiss stocks - Factors to watch on October 19
Brief: FDA Approves Alcon’S BRYTL Eye Drops
Advisory: Alert incorrectly tagged to Omega Interactive Technologies withdrawn